{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-013586","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2022-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.886063+00:00","generated_at":"2026-06-24T06:26:11.856824+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical Q2 revenue $25.1M flat; FDA clears Tablo for home use; FY22 guidance $105-110M","bullets":["Q2 revenue $25.1M flat YoY; net loss ($43.8M) vs ($30.2M); GAAP EPS ($0.92).","FDA cleared 510(k) for Tablo home use; shipments resumed after voluntary hold.","FY 2022 guidance: revenue $105M-$110M (2-7% growth) citing staffing & inflation pressures.","Gross margin improved to 15.1% from 4.2% YoY, but operating expenses rose to $47.5M vs $31.0M.","Cash $295.4M as of June 30; non-GAAP net loss per share ($0.77)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-013586","json":"https://secwatch.observer/filing/0000950170-22-013586.json","markdown":"https://secwatch.observer/filing/0000950170-22-013586.md","text":"https://secwatch.observer/filing/0000950170-22-013586.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017022013586/0000950170-22-013586-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017022013586/om-20220801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T06:26:11.856824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}